OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Summary by AI BETAClose X

OKYO Pharma Limited has transitioned its At-The-Market equity offering facility to Leerink Partners LLC, appointing them as the exclusive sales agent. This move replaces their previous facility with B. Riley Securities Inc. and allows OKYO Pharma to continue accessing capital markets efficiently by selling common shares at prevailing market prices, subject to market conditions. Leerink Partners will receive a commission of 3.0% of gross proceeds from any shares sold under this program, which is intended to enhance financial flexibility for advancing their pipeline, including urcosimod for neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings